Relay Therapeutics Inc

NASDAQGM:RLAY

United States / Healthcare / Biotechnology

Overview

News

5Y Historical Financials

Stock Price

3.06 USD


Key Metrics	Latest
Total Revenue	10.007 M
Adjusted EBITDA	-380.2 M
EBITDA Margin	-3,799.4%
Net Profit Margin	-3,472.4%
Total Assets	871.3 M
Total Debt	48.502 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	82.65	3.03	1.38	25.55	10.01	10.01	25.55	10.01
% Growth		(0.96)	(0.54)	17.50	(0.61)			(0.61)

Adjusted EBITDA	(52.25)	(222.18)	(306.82)	(374.15)	(380.21)	(380.21)	(374.15)	(380.21)
% Margin	(0.63)	(73.35)	(222.17)	(14.65)	(37.99)	(37.99)	(14.65)	(37.99)

Adjusted EBIT	(55.80)	(226.11)	(310.95)	(379.42)	(385.67)	(385.67)	(379.42)	(385.67)
% Margin	(0.68)	(74.65)	(225.16)	(14.85)	(38.54)	(38.54)	(14.85)	(38.54)

Adjusted Net Income	(52.41)	(261.31)	(299.15)	(346.73)	(347.48)	(347.48)	(346.73)	(347.48)
% Margin	(0.63)	(86.27)	(216.62)	(13.57)	(34.72)	(34.72)	(13.57)	(34.72)

Adjusted Basic EPS	(1.23)	(2.75)	(2.67)	(2.83)	(2.43)	(2.43)	(2.83)	(2.43)

Supporting Calculations

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	83	3	1	26	10	10	26	10
% Growth	NA	-96.3%	-54.4%	1749.8%	-60.8%			-60.8%

Cost of Revenue	(97)	(169)	(243)	(326)	(315)	(315)	(326)	(315)
Gross Profit	(14)	(166)	(242)	(301)	(305)	(305)	(301)	(305)
% Revenue	-16.9%	-5492.2%	-17496.3%	-1177.6%	-3052.2%	-3052.2%	-1177.6%	-3052.2%

Research and Development	(100)	(296)	(246)	(330)	(319)	(319)	(330)	(319)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(42)	(60)	(69)	(79)	(80)	(80)	(79)	(80)
Other Inc / (Exp)	100	157	258	336	332	332	336	332
Total Operating Exp	(42)	(198)	(58)	(72)	(67)	(67)	(72)	(67)

Operating Income	(56)	(365)	(299)	(373)	(372)	(372)	(373)	(372)
% Revenue	-67.5%	-12040.3%	-21672.3%	-1460.2%	-3721.9%	-3721.9%	-1460.2%	-3721.9%

Interest Expense	3	1	9	31	35	35	31	35
Pre-tax Income	(52)	(364)	(291)	(342)	(338)	(338)	(342)	(338)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0
Net Income to Company	(52)	(364)	(291)	(342)	(338)	(338)	(342)	(338)
% Margin	-63.4%	-12012.9%	-21036.1%	-1338.7%	-3374.7%	-3374.7%	-1338.7%	-3374.7%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	(52)	(364)	(291)	(342)	(338)	(338)	(342)	(338)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	(178)	0	0	0	0	0	0	0

Net Income to Common	(230)	(364)	(291)	(342)	(338)	(338)	(342)	(338)
% Margin	-278.5%	-12012.9%	-21036.1%	-1338.7%	-3374.7%	-3374.7%	-1338.7%	-3374.7%

As Reported
Basic EPS (Continuing Ops)	(5.40)	(3.82)	(2.59)	(2.79)	(2.36)	(2.36)	(2.79)	(2.36)
Diluted EPS (Continuing Ops)	(5.40)	(3.82)	(2.59)	(2.79)	(2.36)	(2.36)	(2.79)	(2.36)

WA Basic Shares Out.	42.62	95.14	112.23	122.58	142.87	142.87	122.58	142.87
WA Diluted Shares Out.	42.62	95.14	112.23	122.58	142.87	142.87	122.58	142.87

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(52)	(364)	(291)	(342)	(338)	(338)	(342)	(338)
Addback: Net Interest Expense	(3)	(1)	(9)	(31)	(35)	(35)	(31)	(35)
Addback: Other Non Operating Expenses, Total	0	0	0	0	(0)	(0)	0	(0)
Addback: Depreciation & Amortization	4	4	4	5	5	5	5	5
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	1	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	12	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	123	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	3	(12)	(6)	(13)	(13)	(6)	(13)
Adjusted EBITDA	(52)	(222)	(307)	(374)	(380)	(380)	(374)	(380)
% Margin	-63.2%	-7335.2%	-22217.4%	-1464.6%	-3799.4%	-3799.4%	-1464.6%	-3799.4%

Adjusted EBIT	(56)	(226)	(311)	(379)	(386)	(386)	(379)	(386)
% Margin	-67.5%	-7464.7%	-22516.4%	-1485.3%	-3854.0%	-3854.0%	-1485.3%	-3854.0%

Adjusted Net Income Reconciliation
Net Income to Company	(52)	(364)	(291)	(342)	(338)	(338)	(342)	(338)
Addback: Unusual Items	0	139	(12)	(6)	(13)	(13)	(6)	(13)
Less: Tax Benefit of Unusual Items (26%)	0	(36)	3	2	3	3	2	3
Adjusted Net Income	(52)	(261)	(299)	(347)	(347)	(347)	(347)	(347)
% Margin	-63.4%	-8627.1%	-21661.8%	-1357.3%	-3472.4%	-3472.4%	-1357.3%	-3472.4%

Loading Error

Relay Therapeutics Inc

NASDAQGM:RLAY

United States / Healthcare / Biotechnology

5Y Historical Financials